Dexmethylphenidate
Active ingredient: Dexmethylphenidate Hydrochloride
In short: Dexmethylphenidate hydrochloride extended-release is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) .
What is Dexmethylphenidate used for?
Dexmethylphenidate hydrochloride extended-release is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) .
âš Boxed warning (FDA's strongest warning)
Dexmethylphenidate hydrochloride extended-release has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dexmethylphenidate hydrochloride extended-release, can result in overdose and death , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Before prescribing
dexmethylphenidate hydrochloride extended-release,
assess each patient’s risk for abuse, misuse, and addiction.
Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout dexmethylphenidate hydrochloride extended-release treatment, reasses
s each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of
abuse, misuse, and addiction .
Dexmethylphenidate dosage
Prior to treating patients with dexmethylphenidate hydrochloride extended-release, assess:
for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) .
the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome before initiating dexmethylphenidate hydrochloride extended-release .
Patients New to Methylphenidate
The recommended starting dosage of dexmethylphenidate hydrochloride extended-release for patients who are not currently taking dexmethylphenidate or racemic methylphenidate, or for patients who are on stimulants other than methylphenidate are:
Pediatric patients: Start with 5 mg orally once daily in the morning with or without food.
Adult patients: Start with 10 mg orally once daily in the morning with or without food.
Patients Currently on Methylphenidate
The recommended starting dose of dexmethylphenidate hydrochloride extended-release for patients currently using methylphenidate is half (1/2) the total daily dose of racemic methylphenidate.
Patients currently using dexmethylphenidate immediate-release tablets may be given the same daily dose of dexmethylphenidate hydrochloride extended-release.
Titration Schedule
The dose may be titrated weekly in increments of 5 mg in pediatric patients and 10 mg in adult patients. The dose should be individualized according to the needs and response of the patient. Daily doses above 30 mg in pediatrics and 40 mg in adults have not been studied and are not recommended.
Dexmethylphenidate hydrochloride extended-release is administered orally and may be taken whole or the capsule may be opened and the entire contents sprinkled onto applesauce. If the patient is using the sprinkled administration method, the sprinkled applesauce should be consumed immediately; it should not be stored. Patients should take the applesauce with sprinkled beads in its entirety without chewing. The dose of a single capsule should not be divided. The contents of the entire capsule should be taken, and patients should not take anything less than one capsule per day.
If paradoxical aggravation of symptoms or other adverse reactions occur, reduce the dosage, or if necessary, discontinue dexmethylphenidate hydrochloride extended-release. If improvement is not observed after appropriate dosage adjustment over a one-month period, the drug should be discontinued.
How to take Dexmethylphenidate — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Medication Guide).
Abuse, Misuse, and Addiction
Educate patients and their families about the risks of abuse, misuse, and addiction of dexmethylphenidate hydrochloride extended-release, which can lead to overdose and death, and proper disposal of any unused drug . Advise patients to store dexmethylphenidate hydrochloride extended-release in a safe place, preferably locked, and instruct patients to not give dexmethylphenidate hydrochloride extended-release to anyone else.
Risks to Patients with Serious Cardiac Disease
Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with dexmethylphenidate hydrochloride extended-release use. Instruct patients to contact a healthcare provider immediately if they develop symptoms, such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease .
Increased Blood Pressure and Heart Rate
Instruct patients that dexmethylphenidate hydrochloride extended-release can cause elevations of their blood pressure and pulse rate . …
Warnings & precautions
Do not take this medicine if: Hypersensitivity to methylphenidate or other components of dexmethylphenidate hydrochloride extended-release. Hypersensitivity reactions, such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate .
Concomitant treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises .
Dexmethylphenidate hydrochloride extended-release has a high potential for abuse and misuse. The use of dexmethylphenidate hydrochloride extended-release exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Dexmethylphenidate hydrochloride extended-release can be diverted for non-medical use into illicit channels or distribution . Misuse and abuse of CNS stimulants, including dexmethylphenidate hydrochloride extended-release, can result in overdose and death , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Before prescribing dexmethylphenidate hydrochloride extended-release, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store dexmethylphenidate hydrochloride extended-release in a safe place, preferably locked, and instruct patients to not give dexmethylphenidate hydrochloride extended-release to anyone else. Throughout dexmethylphenidate hydrochloride extended-release treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction. …
Dexmethylphenidate side effects
The following are discussed in more detail in other sections of the labeling:
Abuse, Misuse, and Addiction
Known hypersensitivity to methylphenidate or other ingredients of dexmethylphenidate hydrochloride extended-release
Hypertensive Crisis with Concomitant Use of Monoamine Oxidase Inhibitors
Risks to Patients with Serious Cardiac Disease
Increased Blood Pressure and Heart Rate
Psychiatric Adverse Reactions
Priapism
Peripheral Vasculopathy, Including Raynaud’s Phenomenon
Long-Term Suppression of Growth in Pediatric Patients
Acute Angle Closure Glaucoma
Increased Intraocular Pressure and Glaucoma
Motor and Verbal Tics, and Worsening of Tourette’s Syndrome
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adverse Reactions in Studies with
Dexmethylphenidate Hydrochloride Extended-Release in Pediatric Patients with ADHD
The safety data in this section is based on data from a 7-week controlled clinical study of dexmethylphenidate hydrochloride extended-release in 100 (103 randomized) pediatric patients with ADHD ages 6 to 17 years (ages 6 to 12, n = 86; ages 13 to 17, n = 17). …
Drug interactions
Table 5 presents clinically important drug interactions with dexmethylphenidate hydrochloride extended-release.
Table 5: Clinically Important Drug Interactions with Dexmethylphenidate Hydrochloride Extended-Release
Monoamine Oxidase Inhibitors (MAOIs)
Clinical Impact | Concomitant use of MAOIs and CNS stimulants, including dexmethylphenidate hydrochloride extended-release, can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure .
Intervention | Concomitant use of dexmethylphenidate hydrochloride extended-release with MAOIs or within 14 days after discontinuing MAOI treatment is contraindicated.
Antihypertensive Drugs
Clinical Impact | Dexmethylphenidate hydrochloride extended-release may decrease the effectiveness of drugs used to treat hypertension .
Intervention | Monitor blood pressure and adjust the dosage of the antihypertensive drug as needed.
Halogenated Anesthetics
Clinical Impact | Concomitant use of halogenated anesthetics and dexmethylphenidate hydrochloride extended-release may increase the risk of sudden blood pressure and heart rate increase during surgery. …
About this medicine
Dexmethylphenidate hydrochloride extended-release contains dexmethylphenidate hydrochloride, a CNS stimulant. Dexmethylphenidate hydrochloride is the d-threo enantiomer of racemic methylphenidate hydrochloride. Dexmethylphenidate hydrochloride extended-release is an extended-release formulation of dexmethylphenidate with a bi-modal release profile. Each bead-filled dexmethylphenidate hydrochloride extended-release capsule contains half the dose as immediate-release beads and half as enteric-coated, delayed-release beads, thus providing an immediate release of dexmethylphenidate and a delayed release of dexmethylphenidate. Dexmethylphenidate hydrochloride extended-release is intended for oral administration and is available as 5 mg, 10 mg, 20 mg, 25 mg, 35 mg, and 40 mg extended-release capsules.
Chemically, dexmethylphenidate hydrochloride is methyl α-phenyl-2-piperidineacetate hydrochloride, (R,R’)-(+)-. Its molecular formula is C14H19NO2•HCl. Its structural formula is:
Note* = asymmetric carbon center
Dexmethylphenidate hydrochloride is a white to off-white powder. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e304388e-86a6-4335-abae-0ce79c7c99c6. Read the full official label on DailyMed.